Innoviva (INVA) Operating Expenses (2010 - 2026)
Innoviva's (INVA) quarterly Operating Expenses came in at $37.7 million in Q1 2026, up 18.16% YoY from $31.9 million in Q1 2025, and down 64.87% on a QoQ basis from $107.2 million in Q3 2025.
Innoviva (INVA) Operating Expenses (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Operating Expenses data on file, last reported at $37.7 million in Q1 2026.
- Quarterly Operating Expenses rose 18.16% year-over-year to $37.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.3 million (up 14.55% YoY) and the FY2025 annual result came in at $143.9 million, up 11.27% from the prior year.
- Operating Expenses retreated to $37.7 million in Q1 2026, from $107.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $107.2 million in Q3 2025 to a low of -$219.2 million in Q3 2022.
- A 5-year average of $37.4 million and a median of $37.7 million in 2026 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 1956.38% in 2022, down 109.53% in 2022.
- Tracing INVA's Operating Expenses over 5 years: stood at -$219.2 million in 2022, then jumped by 141.85% to $91.7 million in 2023, then climbed by 2.86% to $94.4 million in 2024, then grew by 13.66% to $107.2 million in 2025, then slumped by 64.87% to $37.7 million in 2026.
- The last three Operating Expenses figures came in at $37.7 million (Q1 2026), $107.2 million (Q3 2025), and $34.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 39.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.76 Mn |
| Mar 31, 2026 | 37.68 Mn |
| Sep 30, 2025 | 107.24 Mn |
| Jun 30, 2025 | 34.40 Mn |
| Mar 31, 2025 | 31.89 Mn |
| Sep 30, 2024 | 94.35 Mn |
| Jun 30, 2024 | 30.30 Mn |
| Mar 31, 2024 | 34.28 Mn |
| Sep 30, 2023 | 91.73 Mn |
| Jun 30, 2023 | 75.19 Mn |
| Mar 31, 2023 | 35.23 Mn |
| Sep 30, 2022 | -219.17 Mn |
| Jun 30, 2022 | 87.73 Mn |
| Mar 31, 2022 | 45.34 Mn |
| Sep 30, 2021 | -104.60 Mn |
| Jun 30, 2021 | 4.27 Mn |
| Mar 31, 2021 | 6.04 Mn |
| Dec 31, 2020 | -27.43 Mn |
| Sep 30, 2020 | 4.26 Mn |
| Jun 30, 2020 | 3.16 Mn |